Catarina Travancinha

Dr. Catarina Travancinha


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DGDaniela Garcez
Daniela Garcez
Ana RodriguesAna Rodrigues
Ana Rodrigues
CTCatarina Travancinha
Catarina Travancinha
MPMarcos Pantarotto
Marcos Pantarotto
PCPaulo Costa
Paulo Costa
MFmaria gabriela fernandes
maria gabriela fernandes
Brain metastases represent a major clinical challenge in the management of non-small-cell lung cancer, particularly in patients with epidermal growth factor receptor mutations, constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood–brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small-cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.

8 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DGDaniela Garcez
Daniela Garcez
Ana RodriguesAna Rodrigues
Ana Rodrigues
CTCatarina Travancinha
Catarina Travancinha
MPMarcos Pantarotto
Marcos Pantarotto
PCPaulo Costa
Paulo Costa
MFmaria gabriela fernandes
maria gabriela fernandes
Brain metastases represent a major clinical challenge in the management of non-small cell lung cancer, particularly in patients with epidermal growth factor receptor mutations constituting a leading cause of morbidity and mortality. In recent years, significant advancements have been made in both local therapies and systemic treatments. Nevertheless, managing central nervous system disease remains complex, encompassing challenges such as optimal therapy sequencing, resistance mechanisms, oligoprogression, the role of the blood-brain barrier, diagnostic strategies, and the influence of the brain tumor microenvironment. Despite advances, brain metastases in non-small cell lung cancer remain an unmet need. Local treatments like radiotherapy are effective but carry risks of long-term neurological side effects, while the number and burden of brain metastases remain key prognostic factors. Surgical resection may be considered even in patients with multiple brain metastases to improve clinical status, enable further therapy, and enhance survival and quality of life. With the extension of survival afforded by systemic therapies, optimizing the balance between treatment efficacy and quality of life has become critical. Integrating patient perspectives is essential in navigating these complex clinical decisions.